Challenge:
Anti-nerve growth factor inhibitors are a new class of powerful analgesics in clinical development. They were put on clinical development hold by the FDA in 2012 due to joint-related adverse events in patients. The leader in the development of this class of compounds, Pfizer, needed help in developing a way of clinically evaluating all major joints in subjects entering the Phase III program.
Solution:
Through this groundbreaking work Alacrita built a strong academic team which published a new Imaging Atlas. We co-authored this publication and helped roll out the new program for monitoring joint damage. Pfizer requested our consultants expertise be maintained on the program and to continue the coordination of the radiology team ensuring the imaging quality was at a level required to sustain the successful outcome of the program.
Clinical Development Support
Our seasoned pharmaceutical physicians and functional specialists work to ensure that your program is on the optimal path forward, balancing risk and value, while responding to changes in the external environment. With our network of specialist consultants, our core team leverages 150+ industry-experienced, clinical development strategy and operations consultants, with backgrounds spanning a broad range of therapeutic areas and product modalities.